A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations.
Contemp Clin Trials
; 90: 105892, 2020 03.
Article
en En
| MEDLINE
| ID: mdl-31740428
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
1_doencas_nao_transmissiveis
/
2_muertes_prematuras_enfermedades_notrasmisibles
/
6_diabetes
/
6_endocrine_disorders
/
6_other_malignant_neoplasms
/
6_sense_organ_diseases
Asunto principal:
Piridonas
/
NADPH Oxidasas
/
Pirazolonas
/
Diabetes Mellitus Tipo 1
/
Nefropatías Diabéticas
/
Albuminuria
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Contemp Clin Trials
Asunto de la revista:
MEDICINA
/
TERAPEUTICA
Año:
2020
Tipo del documento:
Article